Hostname: page-component-7b7567c8c-jswmv Total loading time: 0 Render date: 2026-11-15T21:12:50.303Z Has data issue: false hasContentIssue false
  • English
  • Français

Acute and Long-Term Adverse Effects of Antipsychotics

Published online by Cambridge University Press:  07 November 2014

Christoph U. Correll
Get accessRights & Permissions [Opens in a new window]

Extract

Antipsychotics have become the cornerstone of management for many severe mental disorders. Primarily developed for the treatment of schizophrenia, several antipsychotics have been indicated for bipolar mania, bipolar depression, and irritability associated with autistic disorder. Antipsychotics are also used off label for psychotic or refractory depression; refractory anxiety disorders; and conditions associated with agitated or aggressive behaviors. Due to the severity and chronicity of severe mental disorders, the broad range of potential treatment targets, and the relative ease of use of second-generation antipsychotics (SGAs), which are associated with a lower risk of extrapyramidal symptoms (EPS) and tardive dyskinesia (TD), prescribing rates have increased considerably over the last decade. With increased utilization of these medications comes a greater responsibility to appropriately recognize, monitor, and manage side-effect clusters that can adversely affect physical and mental outcomes.

Information

Type
Expert Roundtable Supplement
Information
CNS Spectrums , Volume 12 , Issue S21: Inpatient to Outpatient Status: Clinical Considerations in the Transitional Treatment of Schizophrenia , December 2007, pp. 10 - 14
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1.Buckley, PF. Broad therapeutic uses of antipsychotic medications. Biol Psychiatry. 2001;50(11):912–924.CrossRefGoogle ScholarPubMed
2.Correll, CU, Leucht, S, Kane, JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–425.CrossRefGoogle ScholarPubMed
3.Newcomer, JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1–93CrossRefGoogle ScholarPubMed
4.Miller, DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry. 2004;6(suppl 2):3–7.Google Scholar
5.Haddad, PM, Sharma, SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911–936.CrossRefGoogle ScholarPubMed
6.Michelsen, JW, Meyer, JM. Cardiovascular effects of antipsychotics. Expert Rev Neurother. 2007;7(7):829–839.CrossRefGoogle ScholarPubMed
7.Gardner, DM, Baldessarini, RJ, Waraich, P. Modern antipsychotic drugs: a critical overview. CMAJ. 2005;172(13):1703–1711.CrossRefGoogle ScholarPubMed
8.Marder, SR, Essock, SM, Miller, AL, et al.Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8):1334–1349.CrossRefGoogle ScholarPubMed
9.Kroeze, WK, Hufeisen, SJ, Popadak, BA, et al.H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–526.CrossRefGoogle ScholarPubMed
10.Kim, SF, Huang, AS, Snowman, AM, et al.Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA. 2007;104(9):3456–3459.CrossRefGoogle ScholarPubMed
11.Bymaster, FP, Calligaro, DO, Falcone, JF, et al.Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 1996;14(2):87–96.CrossRefGoogle ScholarPubMed
12.Bymaster, FP, Felder, CC, Tzavara, E, Nomikos, GG, Calligaro, DO, Mckinzie, DL. Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(7):1125–1143.CrossRefGoogle ScholarPubMed
13.Shapiro, DA, Renock, S, Arrington, E, et al.Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400–1411.CrossRefGoogle ScholarPubMed
14.Kroeze, WK, Hufeisen, SJ, Popadak, , et al.H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519–526.CrossRefGoogle ScholarPubMed
15.Richelson, E, Souder, T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci. 2000;68(1):29–39.CrossRefGoogle ScholarPubMed
16.Richelson, E. Neuroleptic binding to human brain receptors: relation to clinical effects. Ann N Y Acad Sci. 1988;537:435–442.CrossRefGoogle ScholarPubMed
17.Richelson, E, Nelson, A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol. 1984;103(3–4):197–204.CrossRefGoogle ScholarPubMed
18.Preskorn, SH, Flockhart, DA. 2006 guide to psychiatric drug interactions. Primary Psychiatry. 2006;13(4):35–64Google Scholar
19.Correll, J. Antipsychotic use in children and adolescents: Minimizing adverse effects to maximize outcomes. Am Acad Child Adolesc Psychiatry. In press.Google Scholar
20.Daniel, DG, Zimbroff, DL, Potkin, SG, et al.Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20(5):491–505.CrossRefGoogle ScholarPubMed
21.Farah, A. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry. 2005;7(6):268–274.Google ScholarPubMed
22. Abilify [Package Insert]. Princeton, NJ: Bristol-Myers Squibb; 2006.Google Scholar
23.Correll, CU. Real-life switching strategies with second-generation antipsychotics. J Clin Psychiatry. 2006;67(1):160–161.CrossRefGoogle ScholarPubMed
24.Lieberman, JA, Stroup, TS, McEvoy, JRet al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.CrossRefGoogle ScholarPubMed
25.Kane, J, Canas, F, Kramer, M, et al.Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res. 2007;90(1–3):147–161.CrossRefGoogle ScholarPubMed
26.Marder, SR, McQuade, RD, Stock, E, et al.Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term placebo-controlled trials. Schizophr Res. 2003;61(2–3):123–136.CrossRefGoogle ScholarPubMed
27.Correll, CU, Kane, JM. One-year tardive dyskinesia rates in children and adolescents treated with second-generation antipsychotics: A systematic review. J Child Adol Psychopharmacol. 2007;17(5):647–655.CrossRefGoogle ScholarPubMed
28.Colton, CW, Manderscheid, RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis [serial online]. 2006 Available at: URL: www.cdc.gov/pcd/issues/2006/apr/05_0180.htm. [Accessed September 24, 2007].Google Scholar
29.Correll, CU. Balancing efficacy and safety in the treatment with antipsychotics. CNS Spectr. 2007;12(10)(suppl 17):12-20, 35.CrossRefGoogle ScholarPubMed
30.American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65:267–272.CrossRefGoogle Scholar
31.Simpson, GM, Glick, ID, Weiden, PJ, et al.Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry. 2004;161:1837–1847.CrossRefGoogle ScholarPubMed
32.McLaughlin, T, Reaven, G, Abbasi, F, et al.Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol. 2005;96(3):399–404.CrossRefGoogle Scholar